We are very excited to expand our neuroimaging focus beyond metabolism and contribute to advancing neuroscience drug development.
Antaros Medical in neuroscience
The need for robust and innovative imaging solutions in neuroscience is rapidly increasing. Drug development is accelerating, driven by disease-modifying programs in Alzheimer’s disease, Parkinson’s disease, and neuroinflammation. Emerging insights into synaptic and neuronal integrity, as well as growing understanding of cerebral microvascular pathology, are broadening the therapeutic landscape, highlighting microvascular dysfunction as a critical determinant of clinical outcomes.
Quantitative magnetic resonance imaging (qMRI) is emerging as a key approach for quantifying brain microstructure and physiology, while positron emission tomography (PET) provides complementary molecular read-outs. Together, these imaging methods enable biomarker-driven decision-making, early proof-of-concept studies, and precise assessment of treatment effects.
As we broaden our neuroimaging capabilities, we look forward to playing an important role in advancing neuroscience drug development.
A new specialized Neuroscience team
To support this expansion, we are delighted to welcome three highly experienced colleagues who will further strengthen our neuroscience capabilities.
Prof. Marco Düring, MD, who brings extensive experience in neuroscience research and strategic leadership within imaging services, will lead this important initiative as VP Neuroscience. He is joined by two experts with long-standing experience in the field: Lukas Pirpamer, PhD, Director of MR Imaging, and Benno Gesierich, PhD, Specialist in Imaging Processing and Software Development.
Together with our existing neuroimaging experts, Catarina Rua, PhD, Director MR Imaging, and Martin Schain, PhD, Director PET Imaging, this group will apply the same Antaros Medical integrated approach that has proven so effective in metabolic disease. Our COO, Kerstin Heurling, PhD, who also has a background in neuroscience research, will be working closely with the group.
In addition, we are pleased to welcome Prof. Bradley MacIntosh (University of Toronto) as an external Scientific Advisor to our Neuroscience team.
These growing needs align closely with Antaros Medical’s way of working. As we expand into neuroscience, we apply the same sharp science, tailored solutions, and dependable delivery that define our work in obesity metabolism, and downstream diseases, bringing our established strengths to a new disease area to bring clarity and to support confident decision-making for our partners.